Development of a multi-step leukemogenesis model of mll-rearranged leukemia using humanized mice

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Moriya, Kunihiko ^a   Suzuki, Makiko ^a   Watanabe, Yohei ^a   Takahashi, Takeshi ^a,b   Aoki, Yoko ^a   Uchiyama, Toru ^a   Kumaki, Satoru ^a   Sasahara, Yoji ^a   Minegishi, Masayoshi ^c   Kure, Shigeo ^a   Tsuchiya, Shigeru ^a   Sugamura, Kazuo ^a,d   Ishii, Naoto ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

^c TOHOKU UNIVERSITY HOSPITAL   (Japan)

^d Miyagi Cancer Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE MONOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INFILTRATION; CELL LINEAGE; CONTROLLED STUDY; FUSION GENE; GENE ACTIVATION; GENE REARRANGEMENT; GENETIC TRANSDUCTION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HEPATOSPLENOMEGALY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKEMOGENESIS; MLL AF10 FUSION GENE; MOUSE; NEWBORN; NONHUMAN; ONCOGENE K RAS; ONCOGENE RAS; PHENOTYPE; UMBILICAL CORD BLOOD;

ANIMALS; BLOTTING, SOUTHERN; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA; MICE; MYELOID-LYMPHOID LEUKEMIA PROTEIN; ONCOGENE PROTEINS, FUSION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS;

EID: 84862667583     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037892     Document Type: Article

References (36)

1. Krivtsov AV, Armstrong SA, (2007) MLL translocations, histone modifications and leukaemia stem-cell development. Nature Reviews Cancer 7: 823-833.
2. Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J, et al. (2009) New insights to the MLL recombinome of acute leukemias. Leukemia 23: 1490-1499.
3. Balgobind BV, Zwaan CM, Pieters R, Van den Heuvel-Eibrink MM, (2011) The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Leukemia 25: 1239-1248.
4. Tomizawa D, Koh K, Sato T, Kinukawa N, Morimoto A, et al. (2007) Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Leukemia 21: 2258-2263.
5. Johnson JJ, Chen W, Hudson W, Yao Q, Taylor M, et al. (2003) Prenatal and postnatal myeloid cells demonstrate stepwise progression in the pathogenesis of MLL fusion gene leukemia. Blood 101: 3229-3235.
6. Liu H, Cheng EH, Hsieh JJ, (2009) MLL fusions: pathways to leukemia. Cancer Biol Ther 8: 1204-1211.
7. Forster A, Pannell R, Drynan LF, McCormack M, Collins EC, et al. (2003) Engineering de novo reciprocal chromosomal translocations associated with Mll to replicate primary events of human cancer. Cancer Cell 3: 449-458.
8. Kennedy JA, Barabé F, (2008) Investigating human leukemogenesis: from cell lines to in vivo models of human leukemia. Leukemia 22: 2029-2040.
9. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, et al. (2007) Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nature Biotechnology 25: 1315-1321.
10. Saito Y, Uchida N, Tanaka S, Suzuki N, Tomizawa-Murasawa M, et al. (2010) Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nature Biotechnology.
11. Shultz LD, Ishikawa F, Greiner DL, (2007) Humanized mice in translational biomedical research. Nature Reviews Immunology 7: 118-130.
12. Ito M, Kobayashi K, Nakahata T, (2008) NOD/Shi-scid IL2rgamma(null) (NOG) mice more appropriate for humanized mouse models. Curr Top Microbiol Immunol 324: 53-76.
13. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, et al. (2002) NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100: 3175-3182.
14. Watanabe Y, Takahashi T, Okajima A, Shiokawa M, Ishii N, et al. (2009) The analysis of the functions of human B and T cells in humanized NOD/shi-scid/cnull (NOG) mice (hu-HSC NOG mice). International Immunology 21: 843-858.
15. Hiramatsu H, Nishikomori R, Heike T, Ito M, Kobayashi K, et al. (2003) Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/gammacnull mice model. Blood 102: 873-880.
16. Kambe N, Hiramatsu H, Shimonaka M, Fujino H, Nishikomori R, et al. (2004) Development of both human connective tissue-type and mucosal-type mast cells in mice from hematopoietic stem cells with identical distribution pattern to human body. Blood 103: 860-867.
17. Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, et al. (2005) Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood 106: 1565-1573.
18. Barabe F, Kennedy JA, Hope KJ, Dick JE, (2007) Modeling the Initiation and Progression of Human Acute Leukemia in Mice. Science 316: 600-604.
19. Wei J, Wunderlich M, Fox C, Alvarez S, Cigudosa JC, et al. (2008) Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell 13: 483-495.
20. Montes R, Ayllon V, Gutierrez-Aranda I, Prat I, Hernandez-Lamas MC, et al. (2011) Enforced expression of MLL-AF4 fusion in cord blood CD34+ cells enhances the hematopoietic repopulating cell function and clonogenic potential but is not sufficient to initiate leukemia. Blood 117: 4746-4758.
21. Fu JF, Hsu CL, Shih LY, (2010) MLL/AF10(OM-LZ)-immortalized cells expressed cytokines and induced host cell proliferation in a mouse bone marrow transplantation model. Int J Cancer 126: 1621-1629.
22. DiMartino JF, Ayton PM, Chen EH, Naftzger CC, Young BD, et al. (2002) The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10. Blood 99: 3780-3785.
23. Kaneko S, Onodera M, Fujiki Y, Nagasawa T, Nakauchi H, (2001) Simplified retroviral vector gcsap with murine stem cell virus long terminal repeat allows high and continued expression of enhanced green fluorescent protein by human hematopoietic progenitors engrafted in nonobese diabetic/severe combined immunodeficient mice. Hum Gene Ther 12: 35-44.
24. Sekine R, Kitamura T, Tsuji T, Tojo A, (2008) Efficient retroviral transduction of human B-lymphoid and myeloid progenitors: marked inhibition of their growth by the Pax5 transgene. Int J Hematol 87: 351-362.
25. Nagai T, Ibata K, Park ES, Kubota M, Mikoshiba K, et al. (2002) A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications. Nat Biotechnol 20: 87-90.
26. Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, et al. (2006) Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 38: 294-296.
27. Tamai H, Miyake K, Takatori M, Miyake N, Yamaguchi H, et al. (2011) Activated K-Ras protein accelerates human MLL/AF4-induced leukemo-lymphomogenicity in a transgenic mouse model. Leukemia 25: 888-891.
28. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, et al. (2008) Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 22: 708-722.
29. Komeno Y, Kitaura J, Kitamura T, (2009) Molecular bases of myelodysplastic syndromes: Lessons from animal models. Journal of Cellular Physiology 219: 529-534.
30. Stubbs MC, Kim YM, Krivtsov AV, Wright RD, Feng Z, et al. (2007) MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment. Leukemia 22: 66-77.
31. Kelly LM, Gilliland DG, (2002) Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 3: 179-198.
32. Greaves MF, Wiemels J, (2003) Origins of chromosome translocations in childhood leukaemia. Nature Reviews Cancer 3: 639-649.
33. Ono R, Kumagai H, Nakajima H, Hishiya A, Taki T, et al. (2009) Mixed-lineage-leukemia (MLL) fusion protein collaborates with Ras to induce acute leukemia through aberrant Hox expression and Raf activation. Leukemia 23: 2197-2209.
34. Rizo A, Horton SJ, Olthof S, Dontje B, Ausema A, et al. (2010) BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells. Blood 116: 4621-4630.
35. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, et al. (2008) Efficient tumour formation by single human melanoma cells. Nature 456: 593-598.
36. Liedtke M, Cleary ML, (2009) Therapeutic targeting of MLL. Blood 113: 6061-6068.